WO2004078725A1 - Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters - Google Patents

Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters Download PDF

Info

Publication number
WO2004078725A1
WO2004078725A1 PCT/EP2004/003052 EP2004003052W WO2004078725A1 WO 2004078725 A1 WO2004078725 A1 WO 2004078725A1 EP 2004003052 W EP2004003052 W EP 2004003052W WO 2004078725 A1 WO2004078725 A1 WO 2004078725A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl group
formula
group
compound
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/003052
Other languages
English (en)
French (fr)
Inventor
Jonathan Frost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Priority to JP2006504814A priority Critical patent/JP4805809B2/ja
Priority to DE602004004767T priority patent/DE602004004767T2/de
Priority to EP04717645A priority patent/EP1603876B1/en
Publication of WO2004078725A1 publication Critical patent/WO2004078725A1/en
Priority to US11/221,023 priority patent/US7135569B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters

Definitions

  • the present invention relates to a process for preparing pyridinyl and pyrimidinyl mono-fluorinated beta keto esters, useful as intermediates for pharmaceutical compounds.
  • an object of the present invention is to provide a process for preparing pyridinyl and pyrimidinyl mono-fluorinated beta keto esters of formula (I):
  • R1 represents a pyridine ring or a pyrimidine ring, the rings being optionally substituted by a C 3 -6 cycloalkyl group, a € M alkyl group, a C 1- alkoxy group, a benzyl group or a halogen atom;
  • R2 represents a hydrogen atom, a C ⁇ -6 alkyl group or a halogen atom; and R3 represents a C ⁇ -6 alkyl group; by reacting with fluorine gas a compound of formula (II)
  • Compounds of formula (I) can comprise one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers and diastereoisomers, as well as their mixtures, including racemic mixtures, form part of the invention.
  • the compounds of formula (I) can be provided in the form of a free base or in the form of addition salts with acids, which also form part of the invention. These salts might be prepared according to well known methods in the art.
  • the compounds of formula (I) might be useful as intermediates for pharmaceutical compounds such as described in PCT/EP02/11127 and PCT/EP02/11128.
  • - a pyridine ring represents a 2, 3 or 4-pyridinyl group
  • - a pyrimidine ring represents a 2, 4 or 5-pyrimidinyl group
  • halogen atom corresponds to a chlorine, bromine or iodine atom
  • a C- ⁇ - 6 alkyl group represents a straight or branched alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-bulyl group, n-pentyl group, isopentyl group, neopentyl group, 1 ,1- dimethylpropyl group, n-hexyl group, isohexyl group, and the like;
  • - a C 3-6 cycloalkyl group corresponds to a cyclic alkyl, having from 3 to 6 carbon atoms.
  • the following examples may be cited: cyclopropyl, methylcyclopropyl, cyclobutyl, and - an alkoxy group corresponds to an -O-alkyl group, wherein the alkyl group is as defined above.
  • the process of the present invention is carried out for the compounds of formula (I) wherein: R1 represents a 3 or 4-pyridinyl group and more preferably a 4-pyridinyl group ; or a 4- or 5-pyrimidinyl group and more preferably 4-pyrimidinyl group, the rings being optionally substituted by a C ⁇ -2 alkyl group, and/or
  • R2 represents a hydrogen atom or a C ⁇ - 3 alkyl group
  • R3 represents a C 1 .3 alkyl group; and more preferably for the compounds of formula (I) wherein:
  • R1 represents an unsubstituted 4-pyridinyl group or 4-pyrimidinyl group
  • R2 represents a hydrogen atom
  • R3 represents a methyl group. According to a further object the process of the invention is carried out for the compounds of formula (I) :
  • the process of fluorination may be carried out following scheme 1.
  • compound of formula (II) may be prepared according to methods described in PCT/EP02/11127 and PCT/EP02/11128.
  • compound of formula (II), wherein R1, R2 and R3 are as defined for compound of formula (I), may be fluorinated using fluorine gas in the presence of one or more acids.
  • the acids being best chosen from formic acid, trifluoroacetic acid, sulfuric acid, trifluoromethanesulfonic acid and hydrofluoric acid.
  • the reaction may be carried in the absence or in the presence of an inert solvent such as acetonitrile or chloroform.
  • the reaction is carried out in the presence of hydrofluoric acid in absence of any solvent.
  • the fluorine gas used in the present invention, is preferably diluted with an inert gas such as nitrogen or helium.
  • concentration of fluorine in inert gas is ranging from 1 to 50 per cent, preferably 2 to 25 per cent and more preferably 5 to 15 per cent by volume.
  • the ratio of fluorine to compound (II) depends on the conditions of the experiments. The molar ratio may range for example from 0.5 to 2, more preferably form 0.7 to 1.5 (fluorine : compound (II)).
  • the reaction may be carried out at temperatures ranging from -78°C to 50°C, preferably from -50°C to 0°C and more preferably from -25°C to -7°C.
  • Compounds of formula (I) may be isolated and purified according to well- known methods in the art. For example when the hydrofluoric acid is used, the excess of acid may be removed by evaporation. The excess of acid may be neutralised and followed by extraction and distillation.
  • compounds of formula (I) wherein R1 , R2 and R3 have the same meaning as defined above with the proviso that compounds of formula (I) is not the ethyl 2-fluoro-3-oxo-3- pyridin-4-yl propanoate. More particularly compound of formula (I) is-the ethyl 2- fluoro-3-oxo-3-pyrimidin-4-yl propanoate.
  • the AHF was removed by evaporation.
  • the resulting liquid (613g) was removed into a vessel.
  • the vessel was washed with saturated sodium carbonate solution. These washings were used in the neutralisation of remain product. Further evaporation of the crude product into nitrogen overnight caused 60g of HF to evaporate.
  • the product mixture was neutralised with sodium carbonate and water. More water was added to bring volume to 9 litres.
  • the mixture was extracted, in portions, with methylene chloride (effectively 5 x 2litres). Extracts were combined, dried (MgSO 4 ), and solvents were removed yielding brown liquid (218.5g).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/EP2004/003052 2003-03-07 2004-03-05 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters Ceased WO2004078725A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006504814A JP4805809B2 (ja) 2003-03-07 2004-03-05 ピリジニル及びピリミジニルモノフッ素化βケトエステルの製造方法
DE602004004767T DE602004004767T2 (de) 2003-03-07 2004-03-05 Verfahren zur herstellung von monoifluorierten pyridinyl- und pyrimidinyl-beta-ketoestern
EP04717645A EP1603876B1 (en) 2003-03-07 2004-03-05 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters
US11/221,023 US7135569B2 (en) 2003-03-07 2005-09-07 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290568A EP1454900A1 (en) 2003-03-07 2003-03-07 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters
EP03290568.9 2003-03-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/221,023 Continuation US7135569B2 (en) 2003-03-07 2005-09-07 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters

Publications (1)

Publication Number Publication Date
WO2004078725A1 true WO2004078725A1 (en) 2004-09-16

Family

ID=32799102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/003052 Ceased WO2004078725A1 (en) 2003-03-07 2004-03-05 Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters

Country Status (9)

Country Link
US (1) US7135569B2 (https=)
EP (2) EP1454900A1 (https=)
JP (1) JP4805809B2 (https=)
CN (1) CN100398518C (https=)
AT (1) ATE353877T1 (https=)
DE (1) DE602004004767T2 (https=)
ES (1) ES2281786T3 (https=)
RU (1) RU2330844C2 (https=)
WO (1) WO2004078725A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027116A2 (en) * 2001-09-21 2003-04-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU556140A1 (ru) * 1975-01-06 1977-04-30 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср (1-Оксоинданил-2)-пиридины в качестве промежуточных продуктов дл синтеза биологически активных соединений с способ их получени
US6300511B1 (en) * 1997-07-18 2001-10-09 F2 Chemicals Limited Catalyzed fluorination of carbonyl compounds
US6455728B1 (en) * 1999-11-01 2002-09-24 Air Products And Chemicals, Inc. Direct fluorination process for preparing high purity 2-fluoro-1,3-dicarbonyl compounds using oxygen as a radical scavenger
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027116A2 (en) * 2001-09-21 2003-04-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. THENAPPAN AND D.J. BURTON, TETRAHEDRON LETTERS, vol. 30, no. 45, 1989, pages 6113 - 6116, XP002282303 *
LINDERMAN, RUSSELL J. ET AL: "Oxidation of fluoroalkyl-substituted carbinols by the Dess-Martin reagent", JOURNAL OF ORGANIC CHEMISTRY , 54(3), 661-8 CODEN: JOCEAH; ISSN: 0022-3263, 1989, XP002237900 *

Also Published As

Publication number Publication date
ES2281786T3 (es) 2007-10-01
JP2006519815A (ja) 2006-08-31
EP1454900A1 (en) 2004-09-08
DE602004004767D1 (de) 2007-03-29
US7135569B2 (en) 2006-11-14
EP1603876A1 (en) 2005-12-14
RU2005131007A (ru) 2006-06-27
CN1771229A (zh) 2006-05-10
EP1603876B1 (en) 2007-02-14
RU2330844C2 (ru) 2008-08-10
ATE353877T1 (de) 2007-03-15
CN100398518C (zh) 2008-07-02
JP4805809B2 (ja) 2011-11-02
US20060058526A1 (en) 2006-03-16
DE602004004767T2 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
US11168060B2 (en) Method for producing 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol
EP3925954B1 (en) Fluorolactone and method for producing same
EP1603876B1 (en) Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto esters
US8937204B1 (en) Processes for isolating fluorinated products
US4977264A (en) Process for the production of 4,5-dichloro-6-ethylpyrimidine
EP2727905A1 (en) Process for producing fluorosulfuric acid aromatic-ring esters
JPS61158947A (ja) 光学活性2−(4−ヒドロキシフエノキシ)プロピオン酸の製法
EP2401253B1 (en) A process for the preparation of etoricoxib
KR100517007B1 (ko) 니코틴산의 제조방법
HU214098B (en) Process for producing 2-alkyl-4-fluoromethyl-thiazole-carboxylic acid alkylesters
US8188294B2 (en) Process for preparing biphenyl imidazole compounds
US6437174B1 (en) Method for producing 2-fluoro-isobutyric acid esters
US5523404A (en) Process for preparing 5-chloro-4-hydroxypyrimidines
WO2022220231A1 (ja) フッ素化物の単離方法
US4522764A (en) Process for the production of α, β-unsaturated carboxylic acid alkyl esters sulfonated in the α-position and compounds obtainable by this process
JPH035466A (ja) フェノキシエチルアミノピリミジン誘導体の製造法
EP0548560A2 (en) Process for the manufacturing of halomaleic and halofumaric esters
EP0111440A1 (en) 2-Aminopyrimidines, their production and use
JP2000136177A (ja) N−アルキル−α−ジアルキルアミノアセトヒドロキサム酸化合物の製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 01680/KOLNP/2005

Country of ref document: IN

Ref document number: 1680/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006504814

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004717645

Country of ref document: EP

Ref document number: 11221023

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005131007

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2004809687X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004717645

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11221023

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004717645

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)